1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Mavacamten Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 2.5 mg
  • 1.3.3 5 mg
• 1.4 Market Analysis by Combination Therapy
  • 1.4.1 Overview: Global Mavacamten Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
  • 1.4.2 Combination with Beta-Blockers
  • 1.4.3 Combination with Calcium Channel Blockers
• 1.5 Market Analysis by Sales Channels
  • 1.5.1 Overview: Global Mavacamten Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
  • 1.5.2 Hospital
  • 1.5.3 Retail
  • 1.5.4 Online
• 1.6 Market Analysis by Application
  • 1.6.1 Overview: Global Mavacamten Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.6.2 Treatment Of Obstructive Hypertrophic Cardiomyopathy
  • 1.6.3 Improvement Of Cardiac Function
  • 1.6.4 Relief Of Symptoms Such As Dyspnea And Fatigue
  • 1.6.5 Others
• 1.7 Global Mavacamten Market Size & Forecast
  • 1.7.1 Global Mavacamten Consumption Value (2021 & 2025 & 2032)
  • 1.7.2 Global Mavacamten Sales Quantity (2021-2032)
  • 1.7.3 Global Mavacamten Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 MyoKardia
  • 2.1.1 MyoKardia Details
  • 2.1.2 MyoKardia Major Business
  • 2.1.3 MyoKardia Mavacamten Product and Services
  • 2.1.4 MyoKardia Mavacamten Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 MyoKardia Recent Developments/Updates

3 Competitive Environment: Mavacamten by Manufacturer

• 3.1 Global Mavacamten Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Mavacamten Revenue by Manufacturer (2021-2026)
• 3.3 Global Mavacamten Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Mavacamten by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Mavacamten Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Mavacamten Manufacturer Market Share in 2025
• 3.5 Mavacamten Market: Overall Company Footprint Analysis
  • 3.5.1 Mavacamten Market: Region Footprint
  • 3.5.2 Mavacamten Market: Company Product Type Footprint
  • 3.5.3 Mavacamten Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Mavacamten Market Size by Region
  • 4.1.1 Global Mavacamten Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Mavacamten Consumption Value by Region (2021-2032)
  • 4.1.3 Global Mavacamten Average Price by Region (2021-2032)
• 4.2 North America Mavacamten Consumption Value (2021-2032)
• 4.3 Europe Mavacamten Consumption Value (2021-2032)
• 4.4 Asia-Pacific Mavacamten Consumption Value (2021-2032)
• 4.5 South America Mavacamten Consumption Value (2021-2032)
• 4.6 Middle East & Africa Mavacamten Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Mavacamten Sales Quantity by Type (2021-2032)
• 5.2 Global Mavacamten Consumption Value by Type (2021-2032)
• 5.3 Global Mavacamten Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Mavacamten Sales Quantity by Application (2021-2032)
• 6.2 Global Mavacamten Consumption Value by Application (2021-2032)
• 6.3 Global Mavacamten Average Price by Application (2021-2032)

7 North America

• 7.1 North America Mavacamten Sales Quantity by Type (2021-2032)
• 7.2 North America Mavacamten Sales Quantity by Application (2021-2032)
• 7.3 North America Mavacamten Market Size by Country
  • 7.3.1 North America Mavacamten Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Mavacamten Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Mavacamten Sales Quantity by Type (2021-2032)
• 8.2 Europe Mavacamten Sales Quantity by Application (2021-2032)
• 8.3 Europe Mavacamten Market Size by Country
  • 8.3.1 Europe Mavacamten Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Mavacamten Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Mavacamten Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Mavacamten Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Mavacamten Market Size by Region
  • 9.3.1 Asia-Pacific Mavacamten Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Mavacamten Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Mavacamten Sales Quantity by Type (2021-2032)
• 10.2 South America Mavacamten Sales Quantity by Application (2021-2032)
• 10.3 South America Mavacamten Market Size by Country
  • 10.3.1 South America Mavacamten Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Mavacamten Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Mavacamten Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Mavacamten Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Mavacamten Market Size by Country
  • 11.3.1 Middle East & Africa Mavacamten Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Mavacamten Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Mavacamten Market Drivers
• 12.2 Mavacamten Market Restraints
• 12.3 Mavacamten Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Mavacamten and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Mavacamten
• 13.3 Mavacamten Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Mavacamten Typical Distributors
• 14.3 Mavacamten Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Mavacamten market size was valued at US$ 986 million in 2025 and is forecast to a readjusted size of US$ 7355 million by 2032 with a CAGR of 18.4% during review period.
Mavacamten is an oral, selective, allosteric inhibitor of cardiac myosin, designed to treat obstructive hypertrophic cardiomyopathy (HCM) by reducing excessive myocardial contractility and improving left ventricular outflow tract obstruction. It modulates actin-myosin cross-bridge formation in a reversible manner, thereby alleviating symptoms such as dyspnea, fatigue, and chest pain while enhancing exercise capacity in patients with symptomatic HCM. As a first-in-class targeted therapy, mavacamten offers a novel pharmacological approach beyond conventional beta-blockers and calcium channel blockers, demonstrating favorable efficacy and safety profiles in clinical trials and becoming an important treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy.In 2025, global Mavacamten production reached approximately 12 million units.
As the first-in-class cardiac myosin inhibitor approved globally, mavacamten has established a core position in the treatment of obstructive hypertrophic cardiomyopathy (oHCM), a rare disease with a long-standing high unmet medical need, owing to its pioneering nature and well‑defined clinical efficacy. Its launch has completely transformed the traditional treatment paradigm, which relied on beta‑blockers, calcium channel blockers, and surgical interventions. By precisely targeting the underlying pathogenesis of the disease, mavacamten significantly improves cardiac function and quality of life in patients. On the global market, the drug has rapidly built brand barriers and established market dominance through its first‑mover advantage and robust physician education programs. In the Chinese market, its successful inclusion in medical insurance has greatly improved accessibility, making it a key driver of the drug’s global growth. Competition in the market is becoming increasingly fierce, with new drugs of the same mechanism entering the market one after another and exerting diversion pressure through differentiated advantages such as convenient administration. This has prompted mavacamten to consolidate its leading position by continuously expanding its indications, accumulating long‑term real‑world data, and optimizing treatment regimens. Overall, the targeted therapy market for hypertrophic cardiomyopathy, in which mavacamten operates, is undergoing rapid expansion. The industry focus is shifting from conventional symptom management to precise etiological treatment, and the market will continue to evolve driven by multiple factors including indication expansion, increased market penetration, and optimization of the competitive landscape.
This report is a detailed and comprehensive analysis for global Mavacamten market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Mavacamten market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mavacamten market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mavacamten market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mavacamten market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Mavacamten
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Mavacamten market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include MyoKardia, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Mavacamten market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
2.5 mg
5 mg
Market segment by Combination Therapy
Combination with Beta-Blockers
Combination with Calcium Channel Blockers
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Treatment Of Obstructive Hypertrophic Cardiomyopathy
Improvement Of Cardiac Function
Relief Of Symptoms Such As Dyspnea And Fatigue
Others
Major players covered
MyoKardia
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Mavacamten product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Mavacamten, with price, sales quantity, revenue, and global market share of Mavacamten from 2021 to 2026.
Chapter 3, the Mavacamten competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Mavacamten breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Mavacamten market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Mavacamten.
Chapter 14 and 15, to describe Mavacamten sales channel, distributors, customers, research findings and conclusion.